INTRODUCTION
Treatment of nonhealing bone defects poses a significant challenge for surgeons worldwide. Bone defects can occur anywhere from head to foot and are most commonly due to trauma, tumor resection and congenital abnormalities. Defects of the craniomaxillofacial skeleton, in particular, can be functionally debilitating, socially incapacitating, and they contribute to a substantial biomedical burden. 1, 2 As native calvarial reossification is limited to infants younger than 2 years-of-age, a variety of methods and materials have been used to treat nonhealing cranial defects in older children and adults. 1 For example, current reconstructive options include autogenous and allogenic grafts, vascularized bone flaps, demineralized bone matrices, alloplastic materials and growth factors. 3, 4 Although each method may achieve craniofacial reconstruction, each carries inherent limitations such as donor-site morbidity, graft resorption, contour irregularities, insufficient autogenous resources, disease transmission, graft-versus-host disease, immunosuppression, structural failure, graft extrusion and infection of foreign material. 4 In an effort to reduce the operations necessary to treat nonhealing bone defects as well as avoid the complications associated with autogenous or alloplastic reconstructions, we aim to develop a strategy to guide endogenous bone healing to overcome critical sized bone defects. If a new therapy to augment native bone healing is to be translatable, we hypothesize that it should be a tactical intervention that is both simple and effective. Accordingly, we have focused on a convergence point in two signaling cascades-the bone morphogenic protein (BMP) and transforming growth factor beta (TGFb) pathways. TGFb and its family members-the activins, nodals, BMPs, anti-Muellerian hormone, myostatins and others-exert profound effects on cell division, migration, organization, adhesion, differentiation and death. 5 As SMAD transcription factors are the biochemical backbone of the TGFb and BMP signaling pathways, we focused our attention on these eight proteins. 6 Only five of the mammalian SMADs (that is, SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8) act as substrates for the TGFb and BMP receptors (BMPR); these are commonly referred to as receptor-regulated SMADs (R-SMADs). SMADs 1, 5, and 8 serve principally as substrates for the BMP and anti-Muellerian receptors, and SMADs 2 and 3 for the TGFb, activin and nodal receptors. 5, 6 SMAD4 is a Co-SMAD and serves as a common partner for all R-SMADs. SMAD6 and SMAD7 are inhibitory SMADs (I-SMADs) that serve as decoys interfering with SMAD-receptor or SMAD-SMAD interactions. [7] [8] [9] [10] As SMAD7 inhibits both TGFb and BMP signaling pathways, our attention was drawn to this protein as a potential therapeutic target.
BMPR activation results in the assembly of the SMAD1/5/8 complex that binds SMAD4, enabling the tetramer to translocate into the nucleus and transcriptionally activate target osteogenic genes (for example, Dlx5). [11] [12] [13] Similarly, TGFb receptor activation results in phosphorylation of the SMAD2/3 complex enabling it to bind SMAD4 and then enters the nucleus to transcriptional activate target angiogenic genes (for example, Pai1).
Although TGFb signaling is well-known to induce fibrosis, its downstream angiogenic targets, have recently been implicated in new blood vessel formation essential for new bone formation. 21, 22 Additionally, noncanonical BMP and TGFb signaling through TGFb activated kinase-1 (TAK1) induces gene target (for example, runtrelated transcription factor 2 (Runx2) and collagen1a1 (Col1a1)) transcription important for new bone formation. 19, 20 Here, we investigate the efficacy of targeted percutaneous Smad7 suppression on the treatment of critical size bone defects.
RESULTS
Smad7 siRNA effectively suppresses Smad7 mRNA and protein expression Percutaneous injection of Smad7 small interfering RNA (siRNA) resulted in significant Smad7 mRNA suppression in the trephine defect at 12 weeks (Figure 1a) . Normalizing the agarose-alone Smad7 mRNA levels to one, nonsense siRNA had little effect on Smad7 mRNA expression (0.87±0.2, not significant). In contrast, Smad7 siRNA significantly knocked down Smad7 mRNA levels by 88 ± 5.2% (0.12 ± 0.05; Po0.001) compared with agarose alone and 86.3±2.5% (Po0.01) compared with nonsense siRNA.
Similarly, the percutaneous injection of Smad7 siRNA resulted in a significant reduction in the nuclear protein levels of Smad7 in the trephine defect at 12 weeks ( Figure 1b) . The nuclear expression level of Smad7 in animals treated with Smad7 siRNA was significantly lower (1567 ± 376 RFU) compared with animals treated with agarose alone (3364 ± 204 RFU; Po0.01) and nonsense siRNA (3288±182 RFU; Po0.01) at 12 weeks.
Smad7 suppression increases intranuclear levels of R-SMADs
Having demonstrated that percutaneous injection of Smad7 siRNA resulted in Smad7 mRNA and Smad7 protein knockdown, we investigated the canonical BMP (SMAD1, 5 and 8) and TGFb (SMAD2 and 3) signaling pathways (Figures 2a and b) . Enzymelinked immunosorbent assays performed on homogenized and fractionated trephine zone protein demonstrated that Smad7 siRNA treatment resulted in a significant increase in Smad1/5/8 translocation into the nucleus (1596±273 RFU v. 629±109 RFU for agarose alone, Po0.01 and v. 546±50 RFU for nonsense siRNA, Po0.01).
Similarly, enzyme-linked immunosorbent assays performed on homogenized and fractionated trephine zone protein demonstrated that Smad7 siRNA treatment resulted in a significant increase in SMAD2/3 translocation into the nucleus (1800 ± 387 RFU v. 957 ± 352 RFU for agarose alone, Po0.05 and v. 1049 ± 415 RFU for nonsense siRNA, Po0.05).
Elevated intranuclear R-SMADs increases target gene transcription As percutaneous injection of Smad7 siRNA increased the nuclear translocation of SMAD1/5/8 and SMAD2/3, we investigated key candidate downstream gene targets in both the BMP and TGFb pathways. To investigate key downstream target genes, we measured Pai1 in the SMAD2/3 pathway and Dlx5 in the SMAD1/5/8 pathway. Percutaneous injection of Smad7 siRNA resulted in a significant increase in both Pai1 and Dlx5 mRNA expression in the trephine defect at 12 weeks (Figure 3a ). Relative to Pai1 and Dlx5 mRNA levels (normalized to 1) in agarose alonetreated animals, we measured minimal change in Pai1 (1.1 ± 0.65 fold change; not significant) and Dlx5 (1.4±0.44 fold change; not significant) mRNA levels in nonsense siRNA-treated animals, and a significant increase in change in Pai1 (3.8 ± 0.25 fold change; Po0.05) and Dlx5 (5.7 ± 0.40 fold change; Po0.01) mRNA levels in Smad7 siRNA-treated animals.
Smad7 suppression increases noncanonical target gene transcription Although SMAD7 suppression was designed to target the convergence point in the canonical BMP and TGFb Smad signaling pathways, we also screened autocatalytic feedback release from ubiquitin-mediated receptor downregulation by investigating noncanoncial (that is, non-Smad) signaling. Although TAK1 phosphorylation activates the MKK3-p38 mitogen-activated protein kinase signaling cascade leading to the induction Runx2 and Col1a1 transcription, TAK1 activity can be indirectly screened by measuring Tak1 transcription. 23 Percutaneous injection of Smad7 siRNA resulted in a significant increase in the noncanonical BMP and TGFb signal, as well as target gene transcription in the trephine defect at 12 weeks (Figure 4 ). Relative to Tak1, Runx2 and Col1a1 mRNA levels (normalized to 1) in agarose alone-treated animals, we measured a minimal change in Tak1 (0.9±0.74 fold change; not significant), Runx2 (1.1±0.68 fold change; not significant) Col1a1 (1.4 ± 0.65 fold change; not significant) mRNA levels in nonsense siRNA-treated animals and a significant increase in Tak1 (5.9±0.56 fold change; Po0.01), Runx2 (7.1±0.92 fold change; Po0.001) and Col1a1 (4.6±0.50 fold change; Po0.01) mRNA levels in Smad7 siRNA-treated animals. Similarly, Smad7 siRNA-treated animals had a significant increase in Tak1 (Po0.01), Runx2 (Po0.001) and Col1a1 (Po0.01) compared with animals treated with nonsense siRNA.
Smad7 suppression significantly improves calvarial healing
Having demonstrated that percutaneous Smad7 siRNA injection increased canonical as well as noncanonical signaling resulting in osteogenic (that is, Dlx5, Runx2 and Col1a1) and angiogenic (that is, Pai1) gene target transcription, we investigated the effects of our siRNA delivery system on cranial defect healing. Using an established cranial defect model, we have previously demonstrated less than 4% healing in untreated animals between week 4 (32.9±13.7%) and week 12 (36.0±5.7%). 24 Full-thickness trephination defects were created and animals received percutaneous injections of agarose alone, nonsense siRNA or Smad7 siRNA. Twelve weeks after trephination, percutaneous injection of Smad7 siRNA resulted in a significant increase bony formation ( Figure 5a ). Compared with animals treated with agarose alone (33.9 ± 2.8% healing; Po0.01) and nonsense siRNA (31.5 ± 11.8% healing, Po0.001), animals treated Smad7 siRNA had 91.2±3.8% healing (Figure 5b ).
Using Gomori trichrome staining for digital color analysis of tissue in the trephine defect, we found marked architectural differences between the agarose alone and nonsense siRNA when compared with Smad7 siRNA-treated animals ( Figure 5c ). In the Smad7 siRNA-treated group, there were abundant osteocytes within the surrounding pink lamellar bone as well as the waves of blue woven bone as compared with the osteocytes found in both the agarose alone and nonsense siRNA treatment groups. Unlike the hypocellular, hypovascular fibrous tissue in the trephine defect of the agarose alone and nonsense siRNA treatment groups, the trephine defect of animals treated with Smad7 siRNA marked visible increase in blood vessels and other hematopoietic Twelve weeks after trephination, percutaneous injection of Smad7 siRNA resulted in a significant increase in bone formation. Healing was assessed by serial micro-CT examination and quantification. (b) Compared with animals treated with agarose alone (33.9 ± 2.8% healing; Po0.01) and nonsense siRNA (31.5 ± 11.8% healing, Po0.001), animals treated Smad7 siRNA had 91.2 ± 3.8% healing. Healing of defects is represented as a fraction of total defect area quantified by micro-CT (c) Gomori trichrome staining demonstrated that Smad7 abundant osteocytes within the surrounding pink lamellar bone as well as the waves of blue woven bone in the Smad7 siRNA-treated animals. Agarose alone and nonsense siRNA treatment resulted in a hypocellular, hypovascular fibrous tissue in the trephine defect. *Po0.01; **Po0.001.
Local Smad7 suppression heals cranial defects J Layliev et al elements. Consistent with our previous work as well as the work of other, we detected no chondrocytes or cartilaginous elements in the trephine defects of animals treated with agarose alone, nonsense siRNA or Smad7 siRNA. [24] [25] [26] DISCUSSION SMAD7 can antagonize TGFb and BMP signaling through various mechanisms. 7, [27] [28] [29] First, SMAD7 forms a stable complex with the TGFb and BMP type I receptors, leading to inhibition of R-SMAD phosphorylation as well as the inhibition of heterocomplex formation between R-SMADs and Co-SMAD. 8 In addition to its roles as a competitive inhibitor, SMAD7 also has an important, and perhaps, principal role in regulating TGFb and BMPR ubiquitination by SMURF ubiquitin ligases.
30,31 SMURF2 (for TGFbR) and SMURF1 (for BMPR) bind to SMAD7, resulting not in immediate receptor ubiquitination and degradation, but in export to the cytoplasm. The SMURF-SMAD7 complex then binds the TGFb or BMPR complex and promotes its ubiquitination and downregulation. [30] [31] [32] [33] The activity of SMAD7 is regulated at many levels, suggesting that there are key points for fine-tuning the responses to TGFb and BMP signaling. To determine whether SMAD7 knockdown was feasible in a mouse cranial defect model, we used a previously established agarose matrix system to deliver nonsense or Smad7 siRNA-liposomal transfection complex. Two percutaneous injections of Smad7 siRNA resulted in significant knockdown of both Smad7 mRNA and SMAD7 protein in the trephine defect at 12 weeks. Although our intention was to investigate the feed forward effects of I-SMAD suppression, we also measured the effects of SMAD7 knockdown on the autocatalytic feedback release from ubiquitin-mediated receptor downregulation by investigating the noncanonical (that is, non-SMAD) signaling.
When ligand binds to the TGFbR-II, it gains access to the GS region of TGFbR-I, catalyzing the phosphorylation of alternating serine (or threonine) residues in the sequence Thr-Thr-Ser-GlySer-Gly-Ser. 27 Phosphorylation of TGFbR-I turns the GS region from a FKBP12-binding site to a binding site for SMAD2/3. 34 SMAD2/3 are then phosphorylated by TGFbR-I and released to propagate the signal by intranuclear translocation. In the case of BMP signaling, the SMAD1/5/8 complex is phosphorylated and released to propagate the signal by intranuclear translocation. As percutaneous injection of Smad7 siRNA resulted in a significant I-SMAD knockdown, we investigated downstream R-SMAD signals for the TGFb (SMAD2/3) and BMP (SMAD1/5/8) pathways. SMAD proteins undergo a constant process of nucleocytoplasmic shuttling, and their nuclear accumulation results from receptormediated phosphorylation events that decrease the affinity of R-SMADs for cytoplasmic anchors and increase their affinity for nuclear factors. 35, 36 Subsequent dephosphorylation of R-SMADs causes their return to the cytoplasm for another round of receptor-mediated phosphorylation and nuclear translocation. 37 This ensures a constant sensing of the receptor activation state by the SMAD pathway. We measured Smad2/3 and Smad1/5/8 transcription, as well as cytoplasmic and nuclear SMAD2/3 and SMAD1/5/8 levels. Percutaneous treatment with Smad7 siRNA resulted in a marked increase in Smad2/3 and Smad1/5/8 mRNA levels as well as an increase in the nuclear translocation of phosphorylated SMAD2/3 and SMAD1/5/8. Activated R-SMAD-SMAD4 complexes develop high affinity and selectivity for target gene promoters by recruiting cofactors; this partnering forms the basis for the breadth of TGFb and BMP transcriptional responses. As only a few of these interactions have been validated, instead of focusing on R-SMAD-SMAD4-partner combinations, we investigated known TGFb and BMP-responsive genes. Although there are numerous downstream osteoblastic program targets, we found that percutaneous Smad7 siRNA treatment significantly increased TGFb (that is, Pai1) and BMP (that is, Dlx5) target gene transcription. Surprisingly, we also found that Smad7 siRNA treatment increased the transcription of noncanonical TGFb and BMP gene targets. This unexpected finding suggests I-SMAD knockdown releases TGFbR and/or BMPR for SMURF-SMAD7 ubiquitination and downregulation, resulting in TAK1 signaling. As mechanistic analysis reveals that the TAK1-MKK3/6-p38 mitogen-activated protein kinase axis activates Runx2, promoting its association with the coactivator cAMP-responsive element-binding protein resulting in Col1a1 transcription, I-SMAD knockdown also then regulates osteoblast genetic programs through noncanonical pathways. 19 This hypothesis is further substantiated by the finding that Tak1 deletion affects not only activation of the p38 mitogen-activated protein kinase signaling cascade, but also activation of the BMPresponsive SMAD1/5/8 complex. 38 Thus, our findings support the notion that coordinated activity of TAK1/RUNX2 and BMP/TGFbactivated SMADs converge to induce the osteogenic phenotype that results in the near-complete bone healing observed in the Smad7 siRNA-treated animals. 39 Although the percent defect closure in percutaneous Smad7 siRNA-treated animals (91.2±3.8%) rivals the efficacy of any previously reported results (25-90% defect closure) for growth factor, cytokine, matrix and cell or stem cell-based therapies in critical sized cranial defects, our purpose was not to show that Smad7 siRNA was equal or even superior to other more conventional forms of therapy, but, instead, to explore the possibility of achieving a meaningful clinical result using a novel percutaneous siRNA strategy. [40] [41] [42] [43] [44] Moreover, we think our surprising finding that Smad7 siRNA treatment increases the expression of both canonical and noncanonical TGFb and BMP gene targets is exciting, and may suggest that siRNA therapies have unexpected and unexplored advantages compared with other forms of therapy. In our proof-of-principle approach, we did not attempt to optimize the dose or frequency of siRNA delivery; we empirically selected the schedule based on our own previous work. 45, 46 As we have found that siRNA-liposomal transfection complex delivery from the agarose matrix system results in target RNA suppression for as long as 35 days (Figure 1 and data not shown), we elected to percutaneously treat animals with only two doses of Smad7 siRNA. This strategy likely suppressed Smad7 expression from post-trephination day 7 through day 84. It is important to note, that during the treatment period numerous cell types, including fibroblastic, osteoblastic and angiogenic cells entered the trephine defect. We made no attempt to determine, which cell types were transfected with Smad7 siRNA nor did we attempt to determine their state of cellular differentiation at the time of transfection. It is likely that all the three cell types and more were transfected and, as is shown here, the end result was canonical and noncanonical TGFb and BMP gene target activation and near-complete cranial defect healing. We feel this limitation in our work is shared by most investigators using the cranial defect healing model. While sorting out, which cells are being treated is a Sisyphean task and, to our knowledge, has never been accomplished, undoubtedly, as technology advances it will become possible. Similarly, although we know that siRNAliposomal transfection complex delivery from the agarose matrix system has no systemic off-target siRNA affects, we did not investigate the local effects of Smad7 siRNA on the meninges or brain. 45 Finally, we selected a natural colloid delivery matrix with agarobiose linear polysaccharide moieties because of its extensive safety record; however, we did not investigate alternate matrices that could, for example, provide sustained siRNA release obviating the need for a second injection.
In summary, we demonstrate that percutaneous matrix-based Smad7 siRNA delivery significantly enhances calvarial bone healing. As this relatively noninvasive and efficacious percutaneous therapy effectively initiates bone forming programs that Local Smad7 suppression heals cranial defects J Layliev et al heal critical sized bone defects, it could open the possibility of outpatient or office-based treatments for nonhealing bone defects.
MATERIALS AND METHODS Animals
All experimental procedures were approved by the New York University Medical Center Institutional Animal Care and Use Committee (IACUC no. 070909-02). Ten to twelve-week-old male wild-type (wt) (C57BLKS/J, no. 662) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Animals were housed in a light and temperature-controlled environments, food and water were given ad libitum.
Calvarial defect model
All animals (n ¼ 90) were anesthetized with an intraperitoneal injection of standard mouse anesthesia cocktail consisting of ketamine (100 mg kg À 1 ), xylazine (20 mg kg
) and acepromazine (3 mg kg À 1 ). After appropriate sedation was obtained, the scalp was shaved and aseptically prepared with povidone-iodine and 70% ethanol, and allowed to dry. A no. 15 scalpel blade was used to open the scalp at the midline, exposing the underlying calvarium. Calvarial defects were made using Â 4 magnification in a nonsuture-associated area of the right parietal bone using a 3 mm diameter trephine under constant saline irrigation. Extreme care was taken to prevent injury to the underlying dura mater ( Figure 6 ). After removing the 3 mm diameter portion of the calvarium, the perimeter of the defect was marked with 2 mm bone maker fiducials (Civco Medical Solutions; Kalona, IA, USA) and the overlying soft tissue was closed with interrupted 6-0 nylon sutures (Ethicon Inc., Somerville, NJ, USA).
Preparation of siRNA and treatment administration
We used our previously developed agarose matrix system to deliver a siRNA-liposomal transfection complex to the cranial defect. 45, 46 The agarose matrix is an Food and Drug Administration approved 12 kDa natural colloid seaweed extract composed of agarobiose linear polysaccharide moieties with an extensive safety record in laboratory use. 47 Nonsense (Silencer select siRNA; Applied Biosciences, Foster City, CA, USA) or Smad7 (Applied Biosciences) siRNA was complexed with a liposomal transfection reagent and incorporated into a cooling (o37 1C) 0.4% (w/v) liquid agarose mixture. 48 The dose of siRNA and ratio of liposomal transfection reagent was established in preliminary studies. The optimal formulation was determined to be the least concentration of siRNA necessary for efficacy and most favorable carrier matrix handling properties. Concentrations of siRNA below that used resulted in partial inhibition of gene expression, whereas higher concentrations provided no additional effect on the protein level.
Seven days after trephination, animals received a percutaneous injection of (1) 250 pmol of Smad7 siRNA in 100 ml agarose; or (2) 250 pmol of nonsense siRNA in 100 ml agarose; or (3) 100 ml of agarose alone. Finger-tip palpation was used to delineate the area of full-thickness calvarial defect and guide the injection ( Figure 6 ). The injection was designed to be delivered in the potential space between the dura mater and epicranial aponeurosis ( Figure 6 ). Percutaneous injection of siRNA-containing agarose or agarose alone was repeated one time (that is, two injections total per animal) on post-trephination day 49. Animals were observed every week during the 12 week study period.
Micro-CT evaluation of calvarial defect healing
Animals were euthanized at postoperative week 12 (n ¼ 10 per group) and calvaria were harvested and processed for micro-computed tomography. Specimens were fixed in 4% paraformaldehyde for 48 h, vertically positioned and horizontally scanned at 16-mm resolution using a SCANCO MEDICAL micro-computed tomography 40. Serial axial images of the calvarial defects were used to generate three dimensional reconstructions. The calvarial defect area was calculated using Adobe Photoshop 7.0 (Adobe Systems Inc., San Jose, CA, USA). The defect area was calibrated against the internal calibrator of the three dimensional images to correct for any subtle magnification differences. Percent defect healing was defined as (1 À (current defect area)/(original defect area)) Â 100%.
qRT-PCR analysis of mediators of osteogenesis 
Protein quantification
Animals were euthanized at postoperative week 12 (n ¼ 10 per group) and calvaria were harvested and processed for RNA (see above) and protein extraction. A 5 mm trephine was used to harvest the previous 3 mm trephine defect containing new bone as well as 1 mm perimeter of native Figure 6 . Percutaneous delivery of Smad7 siRNA. (a) The scalp was incised and the calvarium was exposed in order to create a full-thickness right parietal bone defect using a 3 mm diameter trephine. Care was taken to prevent injury to the underlying dura mater. After removing the 3 mm diameter portion of the calvarium, the perimeter of the defect was marked with 2 mm bone maker fiducials and the overlying soft tissue was closed. (b) Seven days after trephination, finger-tip palpation was used to delineate the area of full-thickness calvarial defect and guide the injection. The injection was designed to be delivered in the potential space between the dura mater and epicranial aponeurosis. Animals received a percutaneous injection of (1) 250 pmol of Smad7 siRNA in 100 ml agarose; or (2) 250 pmol of nonsense siRNA in 100 ml agarose; or (3) 100 ml of agarose alone. (c) In this demonstrative image, the agarose matrix was stained with 0.1% methylene blue to demonstrate the area of agarose matrix delivery. Percutaneous injection of siRNA-containing agarose or agarose alone was repeated one time (that is, two injections total per animal) on post-trephination day 49.
bone. The trephine created a 1 mm kerf, such that the 5 mm trephination contained 3 mm of previous defect, 1 mm of native bone and 1 mm kerf. Harvested bone were immediately placed in tissue extraction buffer (Invitrogen) with protease and RNAse inhibitors (Roche Applied Sciences) (0.1 ml g À 1 tissue) and homogenized (Polytron. Kinematica). Nuclear and cytoplasmic protein fractions were isolated according to a previously described method. Nuclear and cytoplasmic extracts were obtained using NE-PER Nuclear and Cytoplasmic Extraction Reagents (ThermoScientific), following the manufacturer's instructions, except that CERI and CERII were diluted with phosphate-buffered saline at 1:1 and 1:4 ratios, respectively, to avoid over lysis. Further steps for protein extraction were carried out protein extraction using an AllPrep DNA/RNA/Protein Mini Kit (QIAGEN) according to the manufacturer's protocol. To ensure equal loading, protein was quantified using a Pierce 660 nm Protein Assay (Thermo Fisher Scientific, Rockford, IL, USA) and spectrophotometer. The homogenate was subjected to enzyme-linked immunosorbent assay to determine nuclear and cytoplasmic levels of SMADs1, 2, 3, 5, 7 and 8 (all antibodies purchased from Abcam, Cambridge, MA, USA). Briefly, the SMAD7, SMAD2/3 or SMAD1/5/8 capture antibody was added to a 96-well plate. Following blocking, homogenized protein was added. After washes, biotinylated detection antibody was added. After washes, streptavidin-horseradish peroxidase was added. Peroxidase activity was detected with 2,2 0 -azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma, St Louis, MO, USA). The optical density was measured at 450 nm with a microplate reader (Infinite, Tecan, Crailsheim, Germany).
Tissue harvest and histology
Animals were euthanized at postoperative week 12 (n ¼ 10 per group) and calvaria were harvested and processed for histology by immediately fixation in 10% formalin for 48 h and then decalcification in Decal (Decal Chemical Corporation, Tallman, NY, USA) for 24 h. After decalcification, samples were embedded in paraffin. Formalin-fixed, paraffin-embedded tissue samples were cut into 5-mm sections and stained with gomoritrichome to assess for bony architecture.
Statistical analysis
All data are presented as the mean±s.e. of the mean. A one-way analysis of variance with Tukey-Kramer post-hoc analysis was performed for multiple comparisons. Significance was considered to be Po0.05. The number of animals in each group was determined with an a priori power analysis using a standard for adequacy of 80% to reject the null hypothesis of zero correlation using G*Power (G*Power, Melbourne, Australia).
